Sorafenib Tablets 200mg
SORALIEVA 200MG (Sorafenib Tablets 200mg) is a targeted anticancer medicine used in the treatment of specific types of liver cancer, kidney cancer, and thyroid cancer. It contains Sorafenib Tosylate, a multikinase inhibitor that helps slow the growth and spread of cancer cells by blocking certain proteins and signaling pathways involved in tumor development and blood vessel formation.
Cancer cells require a constant supply of nutrients and oxygen to grow and spread. Sorafenib works by targeting multiple kinases involved in cancer cell proliferation and angiogenesis (the formation of new blood vessels that feed tumors). By blocking these pathways, SORALIEVA 200MG helps reduce tumor growth and may slow disease progression in eligible patients.
Unlike conventional chemotherapy, Sorafenib is a targeted therapy designed to interfere with specific molecular mechanisms that support cancer growth. This approach makes it an important treatment option in modern oncology, especially for patients with advanced or metastatic cancers.
SORALIEVA 200MG is commonly prescribed for:
• Hepatocellular Carcinoma (HCC) – Liver Cancer
• Advanced Renal Cell Carcinoma (RCC) – Kidney Cancer
• Differentiated Thyroid Carcinoma (DTC)
• Advanced or Metastatic Solid Tumors
• Long-Term Targeted Cancer Therapy Programs
The medicine is often recommended when surgery or other treatment options are not suitable, or when cancer has progressed despite previous therapies.
Manufactured under stringent pharmaceutical quality standards, SORALIEVA 200MG is designed to provide reliable therapeutic performance and consistent quality. It should only be used under the supervision of qualified oncologists or healthcare professionals experienced in cancer treatment.
Patients undergoing treatment with Sorafenib may require regular blood tests, liver function monitoring, blood pressure assessments, and imaging studies to evaluate treatment effectiveness and manage potential side effects.
Due to its effectiveness in advanced cancer management, SORALIEVA 200MG has become an important component of modern targeted oncology treatment protocols worldwide.
View Details
Axitinib Tablets 5 mg
AXILIEVA 5MG (Axitinib Tablets 5 mg) is a targeted anticancer medicine used in the treatment of advanced kidney cancer (Renal Cell Carcinoma) and certain other oncology indications as prescribed by healthcare professionals. It contains Axitinib, a potent vascular endothelial growth factor receptor (VEGFR) inhibitor that helps slow the growth and spread of cancer cells by reducing the formation of new blood vessels that tumors need to survive and grow.
Cancer cells depend on a steady blood supply to receive oxygen and nutrients. Axitinib works by blocking specific receptors involved in angiogenesis, the process through which tumors create new blood vessels. By inhibiting these pathways, AXILIEVA 5MG helps restrict tumor growth and may contribute to better disease control in eligible patients.
Unlike conventional chemotherapy, Axitinib is a targeted therapy that focuses on molecular pathways associated with cancer progression. This precision-based approach allows oncologists to manage certain cancers more effectively while supporting individualized treatment strategies.
AXILIEVA 5MG is commonly prescribed for:
• Advanced Renal Cell Carcinoma (RCC)
• Metastatic Kidney Cancer
• Targeted Oncology Treatment Programs
• Combination Immunotherapy Protocols
• Long-Term Cancer Management
• Advanced Solid Tumor Treatment Under Specialist Guidance
The medicine may be used alone or in combination with other anticancer therapies depending on the patient’s diagnosis, treatment history, and overall health condition.
Manufactured under stringent pharmaceutical quality standards, AXILIEVA 5MG is designed to deliver reliable therapeutic performance and consistent product quality. The medicine should only be used under the supervision of qualified oncologists and healthcare professionals experienced in cancer treatment.
Patients receiving Axitinib therapy may require regular monitoring of blood pressure, liver function, kidney function, thyroid function, and overall treatment response. These evaluations help optimize treatment outcomes and manage potential side effects effectively.
Due to its effectiveness in targeted oncology care, AXILIEVA 5MG has become an important component of modern kidney cancer treatment protocols and precision cancer therapy programs.
View Details
Sunitinib Malate Capsules 50mg
SUNITCAP 50 MG (Sunitinib Malate Capsules 50 mg) is a prescription targeted anticancer medicine containing Sunitinib Malate 50 mg, a potent Tyrosine Kinase Inhibitor (TKI) used in the treatment of various advanced cancers. It works by blocking specific proteins that promote cancer cell growth and the formation of blood vessels that supply nutrients to tumors.
Cancer cells require a continuous blood supply to grow and spread. Sunitinib helps inhibit angiogenesis (the formation of new blood vessels) and interferes with signaling pathways that cancer cells use for survival and proliferation. This targeted mechanism makes it an effective treatment option for several solid tumors.
Unlike traditional chemotherapy, which affects both healthy and cancerous rapidly dividing cells, Sunitinib specifically targets molecular pathways involved in tumor growth, helping to improve treatment outcomes while supporting long-term disease management.
SUNITCAP 50 MG is commonly prescribed for:
Advanced Renal Cell Carcinoma (Kidney Cancer)
Gastrointestinal Stromal Tumors (GIST)
Pancreatic Neuroendocrine Tumors (pNET)
Metastatic Kidney Cancer
Advanced Solid Tumors
Targeted Cancer Therapy Programs
Long-Term Oncology Management
Precision Oncology Treatment Protocols
The medicine may be used as a first-line treatment or after failure of other therapies, depending on the type and stage of cancer.
Manufactured according to stringent pharmaceutical quality standards, SUNITCAP 50 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Sunitinib therapy require routine monitoring, including blood pressure checks, blood tests, liver function assessments, thyroid evaluations, and regular clinical examinations.
Due to its proven efficacy in multiple cancer types, SUNITCAP 50 MG has become an important treatment option in modern oncology practice.
View Details
Sunitinib Malate Capsules 25mg
SUNITCAP 25 MG (Sunitinib Malate Capsules 25 mg) is a prescription targeted anticancer medicine containing Sunitinib Malate 25 mg, a potent Tyrosine Kinase Inhibitor (TKI) used for the treatment of various advanced cancers. It works by blocking specific proteins that play a critical role in cancer cell growth, tumor progression, and the development of blood vessels that supply nutrients to tumors.
Sunitinib is widely recognized in modern oncology for its targeted mechanism of action. By inhibiting multiple receptor tyrosine kinases involved in tumor growth and angiogenesis, it helps slow the progression of cancer and supports long-term disease control.
Unlike traditional chemotherapy, which may affect both healthy and cancerous cells, Sunitinib specifically targets molecular pathways associated with cancer development. This targeted approach has made it an important treatment option for several advanced and metastatic cancers.
SUNITCAP 25 MG is commonly prescribed for:
Advanced Renal Cell Carcinoma (Kidney Cancer)
Metastatic Renal Cell Carcinoma
Gastrointestinal Stromal Tumors (GIST)
Pancreatic Neuroendocrine Tumors (pNET)
Advanced Solid Tumors
Targeted Cancer Therapy Programs
Precision Oncology Treatment Plans
Long-Term Cancer Management
The 25 mg strength is often used for individualized treatment regimens, dose modifications, maintenance therapy, or patients requiring adjusted doses based on treatment response and tolerability.
Manufactured according to stringent pharmaceutical quality standards, SUNITCAP 25 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Sunitinib therapy require routine monitoring, including blood pressure checks, blood tests, liver function assessments, thyroid monitoring, and regular medical evaluations.
Due to its proven effectiveness in managing several advanced cancers, SUNITCAP 25 MG remains an important medicine in contemporary oncology practice.
View Details
Sunitinib Malate Capsules 12.5mg
SUNITCAP 12.5 MG (Sunitinib Malate Capsules 12.5 mg) is a prescription targeted anticancer medicine containing Sunitinib Malate 12.5 mg, a potent Tyrosine Kinase Inhibitor (TKI) used in the treatment of various advanced and metastatic cancers. Sunitinib works by blocking specific proteins responsible for cancer cell growth, tumor progression, and the formation of blood vessels that supply nutrients to tumors.
Cancer cells rely on multiple signaling pathways to grow and spread throughout the body. Sunitinib targets these pathways by inhibiting several receptor tyrosine kinases, helping to slow tumor growth and reduce the development of new blood vessels required for cancer progression. This targeted approach makes it an important option in modern oncology treatment.
Unlike conventional chemotherapy, which may affect both healthy and cancerous rapidly dividing cells, Sunitinib specifically targets molecular pathways involved in tumor development. This precision-based mechanism supports effective long-term disease management in eligible patients.
SUNITCAP 12.5 MG is commonly prescribed for:
Advanced Renal Cell Carcinoma (Kidney Cancer)
Metastatic Renal Cell Carcinoma
Gastrointestinal Stromal Tumors (GIST)
Pancreatic Neuroendocrine Tumors (pNET)
Advanced Solid Tumors
Targeted Cancer Therapy Programs
Precision Oncology Treatment Plans
Long-Term Cancer Management
The 12.5 mg strength is frequently used for dose adjustments, maintenance therapy, combination dosing schedules, and patients requiring lower doses based on individual treatment response and tolerability.
Manufactured according to stringent pharmaceutical quality standards, SUNITCAP 12.5 MG is designed to ensure consistent quality, safety, and therapeutic effectiveness.
Patients receiving Sunitinib therapy require regular monitoring, including blood pressure assessments, complete blood counts, liver function testing, thyroid evaluations, and clinical examinations to ensure optimal treatment outcomes.
Due to its proven effectiveness in targeted cancer therapy, SUNITCAP 12.5 MG remains an important medicine in contemporary oncology care.
View Details
